Henlius And Eurofarma Entered Into A License Agreement For Henlius' 3 Products In Latin America

Shanghai Henlius Biotech, Inc. ("Henlius") announced this week that it has entered into a license and collaboration agreement with Eurofarma Laboratórios SA ("Eurofarma"), a Brazilian multinational biopharmaceutical company, for the development, manufacturing and commercialization of three biosimilar products in 16 Latin American countries. The three products are HANLIKANG^® (rituximab), HANQUYOU^® (trastuzumab), and HANBEITAI^® (bevacizumab). Under the agreement terms, Henlius will receive up to a total of $50.5 million, including a $4.5 million upfront payment. Eurofarma will acquire exclusive rights to HANLIKANG^® (rituximab) in 12 countries, as well as HANQUYOU^® (trastuzumab) in 11 countries and HANBEITAI^® (bevacizumab) in 15 countries. In addition, Eurofarma will obtain semi-exclusive rights to the three products in Brazil.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Yoko Bian
Goodwin Procter LLP
The New York Times Building
620 Eighth Avenue
New York
NY 10018
UNITED STATES
Tel: [phone]
Fax: [phone]
E-mail: [e-mail]
URL: www.goodwinprocter.com

© Mondaq Ltd, 2022 - Tel. [phone] - http://www.mondaq.com, source Business Briefing